Home・Listă Acțiuni・Becton Dickinson and Co

Becton Dickinson and Co

Închisă

SectorSănătate

183.41 0.86

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

180.71

Maxim

183.72

Indicatori cheie
By Trading Economics
Venit	759M 449M
Vânzări	269M 5B
P/E Medie Sector	30.601 57.002
EPS	3.23
Randament dividend	2.37
Marjă de profit	9.011
Angajați	72,000
EBITDA	-23M 686M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+4.58% upside

Dividende
By Acuity
Randament dividend Medie Sector	2.37% 2.22%
Următoarele câștiguri	5 nov. 2026
Data viitoare de dividende	30 sept. 2026
Următoarea dată ex-dividende	9 sept. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	3.3B 49B
Deschiderea anterioară	182.55
Închiderea anterioară	183.41

Sentimentul știrilor

By Acuity

21%

79%

67 / 340 Clasament în Healthcare

Becton Dickinson and Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 aug. 2026, 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

13 aug. 2026, 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

12 aug. 2026, 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

11 aug. 2026, 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

10 aug. 2026, 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

7 aug. 2026, 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

6 aug. 2026, 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

5 aug. 2026, 19:46 UTC

Becton Dickinson shares are lower today amid broader market declines influenced by ADP's report on private sector job growth miss for July.

4 aug. 2026, 23:16 UTC

Becton Dickinson shares higher in after-market trading, reflecting positive market sentiment amid falling crude oil prices and expectations of reduced inflationary pressures.

3 aug. 2026, 22:51 UTC

Becton Dickinson shares are lower in after-market trading, influenced by a significant downturn in the Health Care Equipment sub-sector.

31 iul. 2026, 19:46 UTC

Becton Dickinson is higher today, showing resilience amid rising bond yields and inflation concerns. The stock remains above its 20-day moving average.

30 iul. 2026, 22:51 UTC

Becton Dickinson and Co shares are lower in after-hours trading, reflecting broader weakness in the Health Care Equipment sub-sector.

29 iul. 2026, 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

28 iul. 2026, 20:02 UTC

News

UBS initiated coverage of Becton Dickinson with a Buy rating and $190 price target, contributing to the stock's upward movement this week.

27 iul. 2026, 20:06 UTC

Becton Dickinson shares are higher, reflecting strength near the upper end of their one-month range amid falling oil prices and declining Treasury yields.

24 iul. 2026, 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

23 iul. 2026, 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

21 iul. 2026, 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

20 iul. 2026, 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Comparație

Modificare preț

Becton Dickinson and Co Așteptări

Obiectiv de preț

By TipRanks

4.58% sus

Prognoză pe 12 luni

Medie 191.8 USD 4.58%

Maxim 210 USD

Minim 175 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBecton Dickinson and Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Becton Dickinson and Co - Dist în ultimele 3 luni.

Sentiment

By Acuity

67 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.